COMP <GO>
BIO vs JNJ // EV/EBITDA & P/E VALUATION
Bio-Rad Laboratories Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: BIO 4
— JNJ 10
▲ EV/EBITDA & P/E VALUATION LEADER: JNJ
LAST: $372.18 (-3.18%) • MKT CAP: $10.28B
valuation
60.4x
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BIO VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BIO | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 51.90% | 67.90% | -16.00 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 0.50% | 25.50% | -25.00 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 60.4x | 18.5x | +41.90 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 3.64% | 2.97% | +0.67 | BIO | /fcf-yield <GO> |
| Operating Margin | 1.80% | 34.70% | -32.90 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 29.40% | 28.50% | +0.90 | BIO | /net-margins <GO> |
| Revenue Growth (YoY) | 0.70% | 6.00% | -5.30 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.59 | 5.59 | -2.00 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 7.20% | -0.20 | BIO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.6 | 60.4 | -8.79 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 1.08 | -0.04 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 12.6x | 23.0x | -10.40 | BIO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.28B | $662.49B | -$652.21B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BIO REV | JNJ REV | BIO GROSS % | JNJ GROSS % | BIO FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.58B | $94.19B | 51.9% | 67.9% | $374.6M | $19.70B |
| FY 2024 | $2.57B | $88.82B | 53.7% | 69.1% | $289.6M | $19.84B |
| FY 2023 | $2.67B | $85.16B | 44.0% | 44.0% | $254.7M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BIO // BETA 1.04
JNJ // BETA 1.08